#USA #Salt Lake City #Co-Diagnostics #Utah Business #Co-Dx PCR

Co-Diagnostics Celebrated at the Utah Business 2025 Innovation Awards

On September 9, 2025, Co-Diagnostics, Inc. (NASDAQ: CODX), a leader in molecular diagnostics, was recognized at the Utah Business 2025 Innovation Awards Summit. The company received this honor for its Co-Dx PCR platform, specifically in the Healthcare and Life Sciences category. The event aims to highlight the innovative companies within Utah that are making significant impacts across various industries.

Award Announcement
Held annually, this awards summit serves as a platform for Utah Business to showcase exceptional innovations and ideas. The judging committee is composed of distinguished professionals and business leaders from Utah, who evaluate submissions based on their potential to address complex challenges through simple yet effective solutions.

Dwight Egan, the CEO of Co-Diagnostics, accepted the award on behalf of the company, expressing gratitude for the acknowledgment of the Co-Dx PCR platform’s innovation and potential future impact. Egan highlighted, "We are honored that the innovation and future impact of the Co-Dx PCR platform have been recognized by this panel of experts... We look forward to the commercialization of the platform next year and to help close the access gap to high-quality PCR diagnostics for patients around the world."

Future of the Co-Dx PCR Platform

The Co-Dx PCR platform is not only revolutionary in diagnostics but also accessible through various modes, including the Co-Dx PCR Home™ and Co-Dx PCR Pro™. This platform is complemented by a mobile app and a suite of assays designed to enhance user experience and increase the reach of molecular diagnostics. It's also remarkable that the platform's tests and software are subject to review by the FDA and other regulatory bodies, ensuring that the product meets the necessary safety and efficacy standards before it enters the market. As Co-Diagnostics continues to develop and prepare for the release, the industry anticipates the potential benefits it will bring to global healthcare access, particularly in high-quality PCR (Polymerase Chain Reaction) diagnostics.

Company Background

Co-Diagnostics, Inc. is a distinguished molecular diagnostics company founded in Utah, specializing in the development and manufacturing of high-performance diagnostics technologies. The company is committed to creating innovative solutions that improve the detection and analysis of nucleic acids (DNA or RNA), essential in various medical applications beyond infectious disease diagnostics. Their pioneering approach serves to create more precise, timely, and affordable diagnostic solutions for the healthcare industry.

Community Impact

The recognition at the Utah Business Innovation Awards not only showcases the advancements made by Co-Diagnostics but also emphasizes its value to the local and global community. The advancements in diagnostic technologies herald a new era of possibilities where patients worldwide have improved access to critical health services. This acknowledgment serves as a testament to the dedication and hard work of the Co-Diagnostics team.

As Co-Diagnostics prepares to commercialize its innovative technology, excitement builds towards what the future holds for patients and healthcare professionals alike. Co-Diagnostics aims to play a vital role in improving healthcare delivery and diagnostics, proving once more that innovative technology can meet pressing medical needs.